These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15695871)

  • 1. Thrombocytopenia following MMR vaccination.
    Kashyape SS; Kashyape PS
    Indian Pediatr; 2005 Jan; 42(1):80-2. PubMed ID: 15695871
    [No Abstract]   [Full Text] [Related]  

  • 2. Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II.
    Knutsson N; Jansson UB; Alm B
    Vaccine; 2006 Jul; 24(31-32):5800-5. PubMed ID: 16765490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a link between MMR vaccine and autism?...and an expert's commentary.
    Child Health Alert; 2002 Dec; 20():1-2. PubMed ID: 12523275
    [No Abstract]   [Full Text] [Related]  

  • 4. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom.
    Miller E; Andrews N; Stowe J; Grant A; Waight P; Taylor B
    Am J Epidemiol; 2007 Mar; 165(6):704-9. PubMed ID: 17204517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination associated thrombocytopenic purpura in children.
    Rajantie J; Zeller B; Treutiger I; Rosthöj S;
    Vaccine; 2007 Feb; 25(10):1838-40. PubMed ID: 17126957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance on MMR vaccine containing L-Zagreb mumps strain.
    Phadke MA; Patki PS; Kulkarni PS; Jadhav SS; Kapre SV
    Vaccine; 2004 Oct; 22(31-32):4135-6. PubMed ID: 15474702
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
    France EK; Glanz J; Xu S; Hambidge S; Yamasaki K; Black SB; Marcy M; Mullooly JP; Jackson LA; Nordin J; Belongia EA; Hohman K; Chen RT; Davis R;
    Pediatrics; 2008 Mar; 121(3):e687-92. PubMed ID: 18310189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing MMR vaccination decisions following a mumps outbreak on a university campus.
    Hamilton-West K
    Vaccine; 2006 Jun; 24(24):5183-91. PubMed ID: 16650916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The relationship between MMR vaccination level and the number of new cases of autism in children].
    Mrozek-Budzyn D; Kiełtyka A
    Przegl Epidemiol; 2008; 62(3):597-604. PubMed ID: 19108524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lack of association between MMR vaccination and the incidence of autism in children: a case-control study].
    Mrozek-Budzyn D; Kiełtyka A; Majewska R
    Przegl Epidemiol; 2009; 63(1):107-12. PubMed ID: 19522237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting.
    Jacobsen SJ; Ackerson BK; Sy LS; Tran TN; Jones TL; Yao JF; Xie F; Cheetham TC; Saddier P
    Vaccine; 2009 Jul; 27(34):4656-61. PubMed ID: 19520201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
    Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case cross-over design.
    Park T; Ki M; Yi SG
    Stat Med; 2004 Jun; 23(12):1871-83. PubMed ID: 15195321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
    Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK;
    Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No evidence of an association between MMR vaccine and gait disturbance.
    Miller E; Andrews N; Grant A; Stowe J; Taylor B
    Arch Dis Child; 2005 Mar; 90(3):292-6. PubMed ID: 15723921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward better vaccine safety data and safer vaccination.
    Braun MM
    Pediatrics; 2008 Mar; 121(3):625-6. PubMed ID: 18310214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.